 Sirolimus
"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 4 | 1 | 5 | | 2000 | 6 | 1 | 7 | | 2001 | 4 | 2 | 6 | | 2002 | 1 | 0 | 1 | | 2003 | 5 | 2 | 7 | | 2004 | 2 | 4 | 6 | | 2005 | 3 | 3 | 6 | | 2006 | 6 | 2 | 8 | | 2007 | 6 | 4 | 10 | | 2008 | 8 | 5 | 13 | | 2009 | 7 | 3 | 10 | | 2010 | 12 | 6 | 18 | | 2011 | 5 | 3 | 8 | | 2012 | 9 | 2 | 11 | | 2013 | 10 | 3 | 13 | | 2014 | 7 | 7 | 14 | | 2015 | 2 | 3 | 5 | | 2016 | 8 | 4 | 12 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Roberti SL, Higa R, White V, Powell TL, Jansson T, Jawerbaum A. Critical role of mTOR, PPAR? and PPARd signaling in regulating early pregnancy decidual function, embryo viability and feto-placental growth. Mol Hum Reprod. 2018 06 01; 24(6):327-340.
-
Davis S, Gralla J, Chan L, Wiseman A, Edelstein CL. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study. Transplant Proc. 2018 Jun; 50(5):1243-1248.
-
Heble A, Everitt MD, Gralla J, Miyamoto SD, Lahart M, Eshelman J. Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures. Pediatr Transplant. 2018 02; 22(1).
-
Siroky BJ, Towbin AJ, Trout AT, Schäfer H, Thamann AR, Agricola KD, Tudor C, Capal J, Dixon BP, Krueger DA, Franz DN. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. J Pediatr. 2017 08; 187:318-322.e2.
-
Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M, Vinks AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. Br J Clin Pharmacol. 2017 05; 83(5):1097-1107.
-
Lesniewski LA, Seals DR, Walker AE, Henson GD, Blimline MW, Trott DW, Bosshardt GC, LaRocca TJ, Lawson BR, Zigler MC, Donato AJ. Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways. Aging Cell. 2017 Feb; 16(1):17-26.
-
McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med. 2016 09 15; 194(6):748-61.
-
Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14; 291(42):21984-22000.
-
Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):2025-2030.
-
Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, Vinks AA. Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol. 2016 08; 5(8):411-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|